Rhythm Stock: Obesity Drug Spurs Analyst Optimism

Rhythm Pharmaceuticals has captured Wall Street's attention following impressive Phase 2 results for its experimental obesity medication, Bivamelagon. The biotech company's shares surged 10% after data revealed the oral treatment achieved a 9.3% BMI reduction in just 14 weeks at its highest dosage (600mg), while the 400mg group saw a 7.7% decrease. These results are comparable to Rhythm's existing injectable treatment, Setmelanotid, but with the significant advantage of oral administration – potentially revolutionizing patient compliance and treatment accessibility.

Strategic Market Position Strengthened

Investment banks have responded enthusiastically to these developments, with Stifel Securities raising its price target from $94 to $123 and Bank of America increasing its target from $73 to $95. Analysts particularly note Bivamelagon's potential to secure Rhythm's market dominance beyond 2040, far outlasting Setmelanotid's patent expiration in 2034. The company is already planning regulatory discussions and aims to optimize formulation by early 2026 before advancing to crucial Phase 3 trials. With a market capitalization of $5.5 billion and shares approaching 52-week highs, investor confidence appears robust as Rhythm positions itself for long-term growth in the specialized obesity treatment market.

Ad

Fresh Rhythm information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Source StockWorld